In vitro diagnostic is a non-invasive technique utilized in early diagnosis and management of diseases. The In vitro diagnostic offers detection of several diseases, and helps in management and maintenance of diseases related conditions. IVD are reagents, instruments, and systems intended to diagnose various diseases that include determination of the state of health, and also cure, mitigate, treat, or prevent diseases. The Europe IVD market accounted for $19,124 million in 2016, and is estimated to reach $26,623 million by 2023, growing at a CAGR of 4.7% during the analysis period of 2017‐2023.
The growth of the IVD market in Europe is primarily characterized by the increase in geriatric & amputee population, high incidence of chronic diseases, and growth in investment on hospital infrastructure. Point-of-care testing is widely used in Europe due to the ease of use and convenience. Recently, European Union (EU) regulatory framework for IVD has introduced significant changes to the previous regulatory framework. This updated policy is expected to enable new product launches at a much faster rate as the new EU regulatory authority aims to provide a robust, transparent, and sustainable regulatory framework.
The market is segmented on the basis of product type, techniques, application, end user, and country. By product type, the market is categorized into reagents, instruments and software & services. On the basis of techniques, it is categorized into immunodiagnostics, blood testing, molecular diagnostics, tissue diagnostics, clinical chemistry, and other IVD techniques. Application segment covered in the study includes infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and other indications. Based on end user, it is classified into hospitals, academic and medical schools, point-of-care testing, and others. By geography, it is analyzed across the UK, Germany, France, Spain, Italy, and Rest of Europe.
KEY BENEFITS FOR STAKEHOLDERS
KEY MARKET SEGMENTS
By Product Type
By End Users
List of players profiled in the report
Cephalosporin Market by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, and Fifth-generation), Type (Branded and Generics), Route of Drug Administration (Injection and Oral), and Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, and Sexually Transmitted Infection) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Cephalosporin is a group of semisynthetic, broad-spectrum antibiotics, which is majorly used to treat bacterial infections. It resembles penicillin and hence is used as an alternative for patients who are allergic to penicillin. It is used in the treatment of a variety of clinical conditions, including pneumonia, skin infections, strep ...
November 2017 | $5370 |View Details>>
The Global Drugs for Malaria market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) of XX% from between 2016 and 2022. This report studies the global Drugs for Malaria market, especially in North America, Europe, Asia-Pacific, South ...
November 2017 | $4960 |View Details>>
In 2016, the Asia-Pacific Drugs for Malaria market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Drugs for Malaria in Asia-Pacific market, especially in China, Japan, Korea, Taiwan, India, Australia, Indonesia, Thailand and ...
November 2017 | $4660 |View Details>>
In 2016, the Drugs for Malaria market size was xx million USD in China, and it will be xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. In China market, the top players include Cipla Guilin Pharmaceutical ...
November 2017 | $3360 |View Details>>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research